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Abstract
Exosomes consist of vesicles that are secreted by several human cells, including tumor cells and neurons, and they
are found in several biological fluids. Exosomes have characteristic protein and lipid composition, however, the
results concerning glycoprotein composition and glycosylation are scarce. Here, protein glycosylation of exosomes
from ovarian carcinoma SKOV3 cells has been studied by lectin blotting, NP-HPLC analysis of 2-aminobenzamide
labeled glycans and mass spectrometry. An abundant sialoglycoprotein was found enriched in exosomes and it was
identified by peptide mass fingerprinting and immunoblot as the galectin-3-binding protein (LGALS3BP). Exosomes
were found to contain predominantly complex glycans of the di-, tri-, and tetraantennary type with or without proximal
fucose and also high mannose glycans. Diantennary glycans containing bisecting N-acetylglucosamine were also
detected. This work provides detailed information about glycoprotein and N-glycan composition of exosomes from
ovarian cancer cells, furthermore it opens novel perspectives to further explore the functional role of glycans in the
biology of exosomes.
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Introduction
Exosomes are membrane vesicles between 40-100 nm in
diameter that are secreted by various cell types, including
tumor cells, neurons, T-cells, dendritic cells and macrophages.
In addition, exosomes were also found in physiological fluids
including plasma, cerebrospinal fluid, urine and malignant
ascites [1,2].
Exosome biogenesis involves the inward budding of
endosomes into multivesicular bodies to form intraluminal
vesicles that are then released to the extracellular space. The
molecular basis of protein sorting during exosomes formation
involves a ubiquitin-dependent mechanism but oligomerization
or partitioning of protein into lipid raft domains may be involved
in the sorting of certain proteins [2]. Exosomes are secreted
from the cell by fusion of multivesicular bodies with the plasma
membrane.
Among other functions, exosomes were found to be
associated with the transmission of pathogenicity among cells,
for example, in tumor progression or neurodegenerative
diseases, and they stimulate the immune system [3,4].
Exosomes can interact with target cells through ligand-receptor
interactions or lipids, and they have been described to fuse
with the plasma membrane or to be internalized via receptor-
mediated endocytosis [5,6]. Lectins and their interactions with
carbohydrates have also been found to play a role in exosome
recognition and uptake by dendritic cells [7] and macrophages
[8].
Exosomes have a unique protein, lipid and glycan
composition. They contain proteins involved in cellular events
including, membrane transport and fusion, biogenesis of
multivesicular bodies, tetraspanins, and they are enriched in
lipid microdomains [2]. Concerning glycosylation, exosomes
were found to contain a conserved glycan signature relatively
to parent cell membranes by lectin array technology [9,10].
Furthermore, specific sialic acid-containing glycoproteins were
previously found in exosomes from SKOV3 cells [6].
In the present work, we have characterized glycoproteins
and N-glycans from ovarian carcinoma exosomes. The
sialoglycoprotein galectin-3-binding protein (LGALS3BP) was
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found to be strongly enriched in exosomes. Furthermore,
exosomes had complex and high mannose glycans.
Materials and Methods
Cell culture
Human ovarian cancer SKOV3 [11] and OVM [12] cell lines
were a generous gift from Prof. Peter Altevogt. Cells were
grown in Dulbecco's Modified Eagle Medium high glucose
(Sigma), supplemented with 10% fetal calf serum, 100 units/ml
penicillin and 0.1 mg/ml streptomycin (Invitrogen), at 37 °C, in
5% CO2, as previously described [13].
Separation of exosomes, microsomal and plasma
membrane fractions
Cellular extracts were obtained by solubilization of
centrifuged cells in 50 mM Tris-HCl pH 7.5, containing 5 mM
ethylenediamine tetraacetic acid, 1% Triton X-100, 0.02%
protease inhibitors cocktail, Complete, Roche, for 30 min.
Confluent cells were cultivated for 48 h in serum-free
medium. The supernatant was collected and centrifuged at
500, 10,000 and 100,000 x g, 10, 20 and 120 min, respectively,
at 4 °C. The pellet of the last centrifugation consisted of crude
exosomes, which was further used for exosome purification by
sucrose gradient as previously described [5,6]. Essentially,
crude exosomes (1 ml suspension) were loaded on top of a
stepwise gradient comprising layers of 2 M (1.5 ml), 1.3 M (2.5
ml), 1.16 M (2.5 ml), 0.8 M (2 ml), 0.5 M (2 ml) and 0.25 M (1
ml) sucrose. The gradients were centrifuged for 2.5 h at
100,000xg in a Beckman SW41Ti rotor. Twelve 1 ml fractions
were collected from the top (1 to 12) and precipitated with 10 %
trichloroacetic acid before immunoblotting or lectin blotting
analysis.
The isolation of the microsomal fraction was performed by
differential centrifugation. Cells were resuspended in
homogenization buffer (1 mM NaHCO3, 0.2 mM CaCl2, 0.2 mM
MgCl2, 1mM spermidine, pH 8.0) [14], disrupted with a pellet
pestle (Sigma) and centrifuged at 600 x g, 10 min, and 15,000
x g, 10 min. The supernatant was further centrifuged at
100,000 x g, for 120 min, and the pellet consisted of the
microsomal fraction.
The isolation of plasma membrane proteins was performed
by cell surface biotinylation as previously described [15].
Typically, the following amounts of protein were obtained from
cells in one T175: 2 mg for total cell extracts, 0.4 mg for the
microsomal fraction, 64 µg for plasma membrane, 36 µg for
crude exosomes and 12 µg for exosomes.
Protein concentration was determined by the bicinchoninic
acid method.
Lectin blotting, immunoblotting and lectin-affinity
chromatography
Proteins were analysed by SDS-PAGE in 10% acrylamide
gels. Glycoproteins were detected by lectin blotting after
transfer to polyvinylidene fluoride as previously described [13].
Concanavalin A (Con A; Sigma), biotinylated Sambucus nigra
agglutinin (SNA) and Maackia amurensis lectin (MAL) (Galab
Technologies) were used. As control of Con A specificity,
incubation was done in the presence of competitive sugar, 0.2
M methyl-α-D-mannopyranoside. As controls for SNA and MAL
specificity exosomes were incubated with sialidases from Vibrio
cholerae, Arthrobacter urefaciens and Streptococcus
pneumoniae as previously described [6]. Immunoblotting was
done as previously described [6] with goat anti-human
GALS3BP polyclonal antibody (R&D) and anti-goat
immunoglobulin G coupled to horseradish peroxidase (Sigma)
as primary and secondary antibodies at 1:2000 and 1:20000
dilutions, respectively. Detection was performed with the
Immobilon Western chemiluminescent (Millipore).
For the separation of MAL-binding proteins, SKOV3 crude
exosomes were solubilized in adsorption buffer (Tris-HCl pH
6.0, 1% 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate) and applied on AffiSpin columns (GALAB
Technologies). After several washes with adsorption buffer,
MAL-binding proteins were eluted from the column with sample
buffer and analysed by SDS-PAGE.
Electron microscopy
Preparation of the exosomes for transmission electron
microscopy was done using the technique published by Théry
et al. [16]. Briefly, centrifuged exosomes were fixed in 2%
paraformaldehyde in PBS overnight. Exosomes on 200 mesh
carbon coated grids (Ted Pella 01800-F) were further fixed with
1% glutaraldehyde in PBS before being contrasted with uranyl-
oxalate and methy cellulose-UA. Grids were observed at 100
kV on a Hitachi-7650 Transmission Electron Microscope and
photographed using an AMT XR41-M Mid-mount camera.
Peptide mass fingerprinting
Gel bands were excised and subjected to in-gel digestion
with trypsin according to the protocol previously described [17].
Tryptic digests of individual gel spots were analyzed by
capillary liquid chromatography-tandem mass spectrometry.
Liquid chromatography was performed using an Ultimate 3000
RSLCnano. Samples were desalted and preconcentrated at a
flow rate of 10 µL/ min on a short C18 Nano Trap Column
Acclaim PepMap (5 µm, 100 A, 100 µm i.d. x 2 cm; LC-
Packings) connected in the front of an analytical capillary
column. For the separation with the C18 PepMap column (180
µm i.d. x 15 cm; LC-Packings), a flow rate of 6 µL/min was
used. For the chromatography, the following solvents were
used: solvent A (H2O, 0.1% formic acid) and solvent B (90%
acetonitrile, 9.9% H2O, 0.1% formic acid). The eluting gradients
used for separation of tryptic digestions were, respectively, 1 to
52% B in 103 min, 52 to 99% B in 1 min, followed by 99% B for
10 min and then by 1% B in 5 min. The chromatography
system was directly coupled to a three-dimensional high-
capacity ion trap (HCTultra ETD II; Bruker Daltonik, Bremen,
Germany) mass spectrometer with an electrospray ionization
source. Instruments were controlled using DCMS Link (Dionex)
and Compass 1.3 (Bruker Daltonics) software. The smart
parameter settings (SPS) were for the target mass 600 m/z and
for compound stability 100%. The full MS scan mode was
standard-enhanced (m/z 300 to 1600). The two most abundant
ions detected in each MS scan were selected for collision-
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induced dissociation (MS/MS) with 1.0 V collision energy. The
peptides were analyzed using the data-dependent MS/MS
mode over the m/z range 100–3000. Raw spectrum data were
processed and Mascot compatible mgf files were created using
DataAnalysis 4.1 software (Bruker Daltonik) with the following
parameters: compounds threshold 100,000, maximum number
of compounds 300, and retention time windows 0.5 min.
Searches were performed using BioTools 3.2 software (Bruker
Daltonik) together with the algorithm on the Mascot web site
(Matrixscience, London, UK) by searching against the NCBI
non-redundant human database. Search parameters were set
as follows: enzyme, trypsin; allowance of up to one missed
cleavage peptide; mass tolerance, 0.3 Da and MS/MS mass
tolerance, 0.3 Da; fixed modification parameter,
carbamidomethylation (C).
N-glycans isolation and analysis of 2-aminobenzamide
labeled N-glycans by NP-HPLC
Total N-glycans isolation from exosome glycoproteins were
performed as previously described [18].
N-glycans were labelled with 2-AB (2-aminobenzamide)
according to the derivatisation method of Bigge [19] with
reagents from Sigma-Aldrich. After derivatisation, the 2-AB
labelled glycan mixtures were purified from excess labelling
reagents by gel filtration using PD MiniTrap G-10 size
exclusion columns from GE Healthcare. The size exclusion
columns were conditioned with 8 ml ultrapure water prior to
sample application. The columns were washed with 700 μl
ultrapure water followed by elution of 2-AB labelled N-glycans
with 500 μl ultrapure water.
Mapping of 2-AB-labelled glycans was done with an
ACQUITY UPLC BEH glycan column from Waters Corporation
(Milford, MA, USA). An HPLC system from Dionex Corporation
(Sunnyvale, CA, USA) with an Ultimate 3000 RS Fluorescence
detector FLD-3400RS was used. Mobile phase A was 85 %
(v/v) acetonitrile and mobile phase B was 250 mM ammonium
formate pH 4.4, at a flow rate of 0.40 mL/min and at a column
temperature of 60°C. Detection was at excitation wavelength =
347 nm, emission wavelength = 420 nm. The gradient was as
follows: starting conditions 88% A and 12% B; a gradient from
1-25 min to 82% A; gradient for 20 min to 70% A; gradient for
10 min to 20% A; increase to 88.0 % A and re-equilibration of
the column isocratically for 10 min. Within an analytical sample
sequence reference standards were run with various
structurally well characterised 2-AB-labelled oligosaccharides.
Enzymatic digestions of 2-AB-labelled N-glycans with various
exoglycosidases were performed with 20-50 pmol of total N-
glycans in 10-20 μl of 0.1 M ammonium acetate buffer pH 5.0.
Digestions with β(1–4)-galactosidase (bovine testes, Prozyme),
α-L-(1–4,6)-fucosidase (bovine kidney, Sigma), α-(1–3,6)-
mannosidase digestion (Jack Bean, Sigma) and neuraminidase
(Arthrobacter ureafaciens, Roche) were performed for 4, 2, 4
and 2 hours, respectively. The glycan incubation mixtures were
diluted with 50 μl H2O and were applied onto a pipette tip filled
with 20-25 μl of porous graphitic carbon (Hypercarb) which had
previously been conditioned with 100 μL 80% acetonitrile
containing 0.1% trifluoroacetic acid and 150 μl water. After
washing with 3 x 150μL H2O, N-glycans were eluted with 150 μl
25% acetonitrile and the eluate was dried in a Speed Vac
concentrator. Samples were stored at -20°C and were
solubilised in 75% acetonitrile / 20% H2O and 2-10 pmol of the
glycan mixture was used for NP-HPLC glycan mapping.
Calculations of peak percentages were done using the
Chromeleon 6.8 software.
N-glycan standards were purchased from Thera-Proteins
Lda (Portugal): di-, tri- (2,4 and 2,6-branched) and fully α2,3
sialylated tetrantennary (with and without repeats)
oligosaccharides with proximal α1-6 linked fucose (Fuc),
oligomannosidic standards Man3-9GlcNAc2, Man3GlcNAc2 with
proximal fucose; other proximal fucosylated standards were
diantennary structures without 1 Gal (both, Man-3 and Man-6
branch), diantennary without 2 galactose (Gal), diantennary
without 2 Gal and without 1 N-acetylglucosamine (GlcNAc)
(both, Man-3 and Man-6 branch); hybrid-type structures with 5
and 6 mannose (Man) residues with and without proximal Fuc.
Diantennary with bisecting GlcNAc and proximal Fuc and
variants lacking one or two Gal were isolated from human
immunoglobulin G. Structures were confirmed by mass
spectrometry and NMR.
Analysis of N-glycans by MALDI-TOF MS
Glycans were analysed with a Bruker ULTRAFLEX time-of-
flight (TOF/TOF) instrument. Mass spectra were recorded in
the reflector and positive ion mode. Samples of 1 μl at an
approximate concentration of 5 pmol.μl-1 were mixed with
equal amounts of the matrix 2,5-dihydroxybenzoic acid. The
mixture was spotted onto a stainless steel target and dried at
room temperature before analysis. Structures were tentatively
assigned to various N-glycans on the basis of their observed
masses in comparison to the calculated masses of known N-
glycans. Further annotation of N-glycans and database search
were performed using the Glyco-Peakfinder platform [20].
Further annotation of N-glycans and database searches were
performed using the GlycoWorkbench software [21].
Analysis of 2-AB labeled oligosaccharides by LC-ESI-
TRAP-MS
The 2-AB labeled oligosaccharide mixture was analyzed by
capillary liquid chromatography-tandem mass spectrometry on
the same system used for the peptide analysis but with
different parameter settings as follows. Samples were directly
injected onto a C18 PepMap column (180 µm i.d. x 15 cm; LC-
Packings) at a flow rate of 8 µL/min. The gradient sequence
used for chromatographic separation was: 0% B for 5 min; 0%
to 35% B in 15 min; 35% to 95% B in 5 min, re-equilibration
with isocratic 0% B for 10 min. The smart parameter settings
(SPS) were set for the target mass 700 m/z and for compound
stability 100 %. The full MS scan mode was standard-
enhanced (m/z 100 to 2000). The most abundant ion detected
in each MS scan was selected for collision-induced dissociation
(MS/MS) with 1.4 V collision energy. Ions of an m/z value in the
ranges m/z 703.7-704.7 and m/z 771.4-772.4 were
preferentially selected. This setup was used for an initial
identification of the glycans. Afterwards, a second analysis with
the same LC-parameter settings and different MS-settings was
performed. In two further runs the target values of m/z 772.4 or
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704.2 respectively were isolated and fragmented. Raw
spectrum data were then processed using DataAnalysis 4.1
software (Bruker Daltonics). The MS2 fragmentation spectra
acquired for each glycan were integrated into one averaged
spectrum. Fragmentation analysis was performed with the help
of GlycoWorkbench (ver. 2.1) [21].
Results
Identification of sialoglycoproteins specific to
exosomes
The microsomal fraction, plasma membrane and crude
exosomes from SKOV3 cells have been analysed by lectin
blotting with the lectins MAL (binds NeuAcα2,3Galβ1,4GlcNAc/
Glc), SNA (binds NeuAcα2,6Gal/GalNAc) and Con A (binds α-
mannosyl containing branched glycans predominantly of the
high-mannose followed by hybrid- and biantennary complex
type). The enriched microsomal fraction was obtained by
differential centrifugation (100,000 x g pellet after clarification of
the cell extract at 15,000 x g) [22], the plasma membrane
enriched fraction was obtained after cell surface protein
biotinylation followed by streptavidin-agarose affinity [15], and
the crude exosomes consisted of the pellet of the cell
supernatant centrifugation at 100,000xg (this fraction is
enriched in exosomes and also contains other vesicles that are
produced by the cells) [5,6]. MAL detected a major band at
approximately 110 kDa in the crude exosomes, which was only
faintly detected in the microsomal fraction or in the plasma
membrane (Figure 1A, indicated with an asterisk). SNA
detected two bands at apparent molecular mass of 260 kDa
and between 80 and 110 kDa, which were almost not detected
in the microsomal fraction nor in the plasma membrane (Figure
1A, indicated with asterisks). Digestion with sialidases from
Vibrio cholerae, Artrobacter urefaciens (cleave α2,3/6-linked
sialic acid) and Streptococcus pneumoniae (cleaves α2,3-
linked sialic acid) abolished MAL binding, whereas digestion
with the former two but not the later abolished SNA binding
thus corroborating the specificity of binding as previously
reported [6]. Concanavalin A also showed a specific binding
pattern for the crude exosomes. Incubation in the presence of
0.2 M methyl-α-D-mannopyranoside abolished detection
corroborating the specificity of binding. These results showed
that the glycosylation or glycoprotein profiles of crude
exosomes were distinct from those of the microsomal fraction
or plasma membrane.
We then aimed at identifying the MAL-binding glycoprotein
that was enriched in exosomes in view of its abundance and
specificity. With that purpose solubilized proteins from crude
exosomes were fractionated by MAL affinity chromatography
(Figure 1B). Marked bands 1 to 21 (Figure 1B) have been
excised and analysed by peptide mass fingerprinting after
trypsin hydrolysis. For comparison bands a to j (Figure 1B)
from crude exosomes were also analysed by peptide mass
fingerprinting (Table 1). Identified proteins are shown in Table
1. Several glycoproteins have been identified in the MAL
eluate: bands 1, 2, 4-8, 10, 12. Cytoplasmic proteins
(11,13–21) were also identified but they were due to non-
specific binding to the resin since cytoplasmic glycoproteins do
not contain sialic acid.
In the mass region of 100 kDa bands 4 to 8 and 10 (Table 1)
were identified as the galectin-3-binding protein (LGALS3BP).
LGALS3BP has a predicted mass of 65,331 based on the
amino acid composition, but its detection around 100 kDa
indicated that it is heavily glycosylated, and, therefore, the
different bands 4 to 8 and 10 may correspond to distinct
glycoforms, which is in agreement with the detection by MAL-
lectin blotting as a broad band. Furthermore, the presence of
glycans can impair the binding of the Coomassie dye to the
protein thus explaining that a stronger detection was not
observed [23].
Crude exosomes were further purified by sucrose gradient as
previously described [5,6] and fractions were analysed by
immunoblot for the conventional exosome marker Tsg101
(tumor susceptibility gene 101; protein involved in the formation
of multivesicular endosomes) [24], CD9 [6] and LGALS3BP
(Figure 2). Fractions 2-5 contained Tsg101, CD9 and also
LGALS3BP (detected as a strong signal by immunoblot and
MAL lectin blot). Since CD9 is also present at the plasma
membrane and has recently been found in extracellular
vesicles other than exosomes [24], biotinylated plasma
membrane proteins were also analysed for comparison (Figure
2A). As expected CD9 was detected at the plasma membrane
contrary to Tsg101. Concerning LGALS3BP it was not detected
at the plasma membrane which supported its specificity as an
exosome marker.
Crude exosomes and purified exosomes were also
visualized by electron microscopy. In agreement with the
detection of biochemical markers, both preparations contained
vesicles with exosome characteristics: cup-shaped vesicles up
to approximately 100 nm (Figure 2 B,C, arrows), and smaller
vesicles between approximately 30 and 50 nm (Figure 2 B,C,
closed arrowheads). Larger vesicles or aggregates were also
observed in crude exosomes and almost not detected in
purified exosomes (Figure 2B, opened arrowhead).
N-glycosylation of glycoproteins from exosomes
N-Glycans have been released from glycoproteins of purified
exosomes with peptide N-glycosidase F, fluorescently labeled
with 2-aminobenzamide (2-AB) and analysed by NP-HPLC
(Figure 3). Peaks corresponding to high mannose glycans were
found in exosomes and identified by their retention times in
comparison with the reference standards (Figure S1, Table S1)
and by their sensitivity toward mannosidase digestion (Figure
3, second panel). Peaks corresponding to sialylated complex
glycans were also found in exosomes, which corresponded to
the peaks that disappeared after digestion with α2,3/6 specific
sialidase (Figure 3, third panel). Ten desialylated complex
glycans (shown in Figure 3, third panel) have been identified by
comparison with the retention times of reference
oligosaccharide standards (Figure S1; Table S1) and
considering the profiles obtained after digestion with
exoglycosidases (Figure 3). Complex glycans of the di-, tri- and
tetraantennary type were found. Furthermore, diantennary
glycans containing bisecting GlcNAc (peaks 3, 6) were also
detected. Some of the structures were partially truncated
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(peaks 1, 2, 3), which could be due to the presence of
glycosidases in the medium.
Desialylated N-glycans have also been analysed by MALDI-
TOF MS (Figure 4). Based on the m/z values, the information
from the NP-HPLC analysis/exoglycosidase digestion (Figure
3) and the N-glycan biosynthetic pathway compatible glycan
structures have been proposed for the major peaks (Table 2).
The exosomes contained complex glycans of the di-, tri- and
tetraantennary type with or without proximal Fuc and high
mannose glycans; structures lacking Gal residues have also
been found (Table 2). The presence of complex and high
mannose glycans was also detected by MALDI-TOF MS in
crude exosomes from another ovarian carcinoma cell line
(OVM) (Figure S2).
Peaks at m/z 2012.7 and m/z 2215.8 (detected at 2110.8 Da
and 2313.9 Da, respectively, after derivatization with 2-AB)
were analysed by LC-ESI Ion Trap MS and fragmentation by
collision induced dissociation (CID). Fragments at m/z 910.25,
1038.29 and 1056.35 derived from the parent ion at 2012.7
identified a diantennary complex glycan with proximal Fuc and
bisecting GlcNAc (Figure S3). Fragments at m/z 1442.28 and
1460.39 derived from the parent ion at 2215.8 identified a
triantennary complex glycan with proximal Fuc and bisecting
GlcNAc (Figure S4). A mass signal at m/z 2215.8 by MALDI-
TOF MS was also found in crude exosomes from the OVM
ovarian carcinoma cell line (Figure S2).
Discussion
Exosomes are secreted vesicles that are produced from the
fusion of multivesicular bodies with the plasma membrane and
present specific biochemical and molecular characteristics. In
Figure 1.  Glycoproteins from membrane fractions of SKOV3 cells.  A. Lectin blotting of glycoproteins from cell extract (Ext),
microsomal fraction (MF), plasma membrane (PM), intracellular fraction (IC) that consisted of non-biotinylated proteins, cytoplasmic
fraction (Cyt) that consisted of the supernatant of the microsomal fraction and crude exosomes (Exosc) were analysed. Three μg
total protein were applied per lane. Detection was performed using the chemiluminescent method. * Correspond to most abundant
sialoglycoproteins enriched in the exosomes. Results were representative of at least two independent experiments. B. SDS-PAGE
analysis of vesicle proteins from SKOV3 cells for peptide mass fingerprinting. A. MAL-binding glycoproteins (bands 1 to 21 identified
in Table 1) and total vesicles proteins (bands a to j were identified in Table 1). Detection was with Coomassie G-250.
doi: 10.1371/journal.pone.0078631.g001
Glycosylation in Ovarian Cancer Exosomes
PLOS ONE | www.plosone.org 5 October 2013 | Volume 8 | Issue 10 | e78631
Table 1. Identification of MAL-binding glycoproteins based
on peptide mass fingerprinting.
Band Protein name
Accession
number
Molecular
mass
Matching
peptides
Sequence
coverage ExoCarta
MAL-
lectin       
1 laminin, alpha 5,isoform CRA_c
gi|
119595780 411358 24 7 +
2 laminin B2chain gi|186964 183195 14 9 +
3 unnamedprotein product gi|37138 133321 8 7 -
4
galectin-3-
binding protein
precursor
gi|5031863 66202 12 24 +
5
galectin-3-
binding protein
precursor
gi|5031863 66202 25 40 +
6
galectin-3-
binding protein
precursor
gi|5031863 66202 27 40 +
7
galectin-3-
binding protein
precursor
gi|5031863 66202 15 27 +
8
galectin-3-
binding protein
precursor
gi|5031863 66202 13 25 +
9 bovine albumin gi|74267962 71186 52 53 +
10
galectin-3-
binding protein
precursor
gi|5031863 66202 7 12 +
11 pyruvate kinase gi|35505 58411 7 16 +
12 cathepsin Dpreproprotein gi|4503143 45037 16 40 +
13
mutant beta-
actin (beta'-
actin)
gi|28336 42128 13 31 +
14 annexin A2isoform 2 gi|4757756 38808 19 58 +
15 annexin A1 gi|4502101 38918 8 27 +
16
L-lactate
dehydrogenase
A chain isoform
1
gi|5031857 36950 9 21 +
17 annexin A1 gi|4502101 38918 8 23 +
18 syntenin gi|2795863 32568 11 30 +
19
proteasome
subunit alpha
type-2
gi|4506181 25996 6 34 +
20 prosome beta-subunit gi|551547 25950 3 12 +
21 macropainsubunit delta gi|296734 19590 4 16 +
Exosc       
the present work, we have identified the sialoglycoprotein
LGALS3BP as an exosome marker from ovarian carcinoma
cells and we also characterized the N-glycans from exosomes.
LGALS3BP is a secreted glycoprotein that has been found in
the extracellular matrix and in body fluids, in exosomes from
cancer cells, urinary and plasma exosomes [25] and in
prostasomes, which are exosome-like vesicles secreted by the
prostate [26]. It has been found in several cancers where it has
a negative prognostic value, it mediates cell adhesion [27] and
it has immunostimulatory properties [28]. Exosomes interact
with target cells and, therefore, they are responsible for the
transmission of pathogenic proteins among cells in
neurodegenerative diseases and also for the activation of the
immune system [1]. Several mechanisms underlie the
exosome/target cell recognition that include ligand-receptor
interactions, with subsequent fusion of vesicles with the plasma
membrane or internalization of whole vesicles via endocytic
pathways [1,6]. Several proteins have been shown to be
involved in the interaction, for example, integrins (beta1 and
beta2) from B cell exosomes mediate adhesion to collagen-I,
fibronectin, and tumor necrosis factor-alpha-activated
fibroblasts [29], and the intercellular adhesion molecule 1 from
exosomes mediates interaction with the lymphocyte function-
associated antigen 1 underlying exosome capture in cells of
the immune system [1]. To our knowledge LGALS3BP has not
previously been described to be involved in exosome/target cell
interaction, however, since it is known to bind several proteins
that are found on the cell surface, such as, collagens IV, V, and
VI, fibronectin and nidogen and galectin-3 [30] and integrin,
beta1 [31], it is possible that due to its enrichment in exosomes
it could play an important role in exosome/target cell interaction
via components of the extracellular matrix with implications in
exosome uptake. Further experiments are required to elucidate
Table 1 (continued).
Band Protein name
Accession
number
Molecular
mass
Matching
peptides
Sequence
coverage ExoCarta
a bovine albumin gi|74267962 71186 51 57 +
b histonemacroH2A1.2 gi|3493529 39748 10 37 +
c annexin A2 gi|56967118 38808 22 64 +
d histone H1b gi|356168 21721 13 38 +
e histone H1.2 gi|4885375 21352 12 36 -
f
keratin, type II
cytoskeletal 2
epidermal
gi|
47132620 65678 14 25 -
g histone H2B gi|1568551 13928 15 81 -
h histone H2Btype 1-H gi|4504269 13884 16 81 -
i histone H2Atype 1-C gi|4504245 14097 12 53 +
j nucleosomecore particle
gi|
347447327 11641 14 78 +
doi: 10.1371/journal.pone.0078631.t001
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this matter. Supporting the presence of LGALS3BP in other cell
lines was our previous observation of a strong MAL-binding
glycoprotein at approximately 100 kDa in crude exosomes of
ovarian carcinoma GG and m130 cells (data not shown), or H4
neuroglioma and HEK293 cells [6].
Figure 2.  Characterization of exosomes obtained from SKOV3 cell supernatants.  A) Immunoblotting of LGALS3BP in purified
exosomes and plasma membrane. SKOV3 cell extracts (Ext), crude exosomes (Exosc), biotinylated plasma membrane proteins
(PM), and fractions from the sucrose gradient used for Exosc fractionation (F1, F2-5, purified exosomes, F6-7, F8-11 and F12).
Three µg protein were applied per lane with the exception of F1, F6-7 and F12, where 20% of the amount obtained from the sucrose
gradient was used. Detection was by the chemiluminescent method. Results were representative of two independent experiments.
B) Electron microscopy visualization of crude exosomes (pellet collected after centrifugation at 100,000xg of pre-cleared
supernatant). C) Electron microscopy visualization of purified exosomes (fractions 2 to 5 of sucrose gradient). Arrows, cup-shaped
vesicles; open arrowhead, vesicles larger than 100 nm; closed arrowheads, vesicles approximately from 30 to 50 nm. The scale bar
corresponds to 100 nm.
doi: 10.1371/journal.pone.0078631.g002
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Figure 3.  NP-HPLC analysis of 2-AB labeled N-glycans from purified exosomes.  N-glycans were digested with mannosidase
(M), sialidase (S), galactosidase (G) and fucosidase (F) as indicated. M5 to M9 consist of high mannose glycans Man5GlcNAc2 to
Man9GlcNAc2, respectively. Structures of components from peaks 1 to 10 were identified by comparison with retention times of
standards (Figure S1, Table S1) and after digestion with exoglycosidases.
doi: 10.1371/journal.pone.0078631.g003
Figure 4.  MALDI-TOF MS analysis of desialylated N-glycans from purified exosomes of SKOV3 cells.  The m/z values of the
first detected isotopic mass for major peaks are shown. Proposed compositions and compatible structures are presented in Table 2.
doi: 10.1371/journal.pone.0078631.g004
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LGALS3BP has seven potential N-glycosylation sites which
are occupied for truncated forms expressed in HEK293 cells
[30]. The extensive N-glycosylation explains the broad band
that we have observed around 110 kDa. The strong binding by
the lectin MAL shows that it contains sialic acid and indicates
that most of the glycans are of the complex-type. Further
studies are required to elucidate if certain glycoforms are
specifically enriched in the exosomes.
Several other MAL-binding glycoproteins have also been
identified in crude exosomes, such as laminin or cathepsin D,
that had already been found by others in exosomes and are
presented in the database Exocarta 2012 [25].
Concerning protein N-glycosylation in exosomes, the
predominance of complex glycans has been found, with
relatively high amounts of sialylation. This is in agreement with
other reports where the enrichment of complex N-linked
glycans into tumor microvesicles has been found [10].
However, exosomes also contained high mannose glycans,
which is in agreement with the finding of this type of structures
Table 2. Observed mass signals (m/z) by MALDI-TOF MS
analysis and proposed composition of the N-glycans from
exosomes.
m/z
Proposed
compositions
Compatible
structures NP-HPLC Peak
1257.5 (1257.5) Hex5HexNAc2 M5 M5
1419.6 (1419.5) Hex6HexNAc2 M6 M6
1581.7 (1581.5) Hex7HexNAc2 M7 M7
1646.6 (1647.6) dHex1Hex4HexNAc4 FA2G1 -
1663.7 (1663.6) Hex5HexNAc4 A2G2 4
1743.8 (1743.6) Hex8HexNAc2 M8 M8
1809.8 (1809.7) dHex1Hex5HexNAc4 FA2G2 5
1850.7 (1850.7) dHex1Hex4HexNAc5 FA3G1, FA2BG1 -
1906.8 (1905.6) Hex9HexNAc2 M9 M9
2012.9 (2012.7) dHex1Hex5HexNAc5 FA3G2, FA2BG2 7, 6
2028.8 (2028.7) Hex6HexNAc5 A3G3 8
2174.9 (2174.8) dHex1Hex6HexNAc5 FA3G3 9
2215.8 (2215.8) dHex1Hex5HexNAc6 FA4G2, FA3BG2 -
2377.9 (2377.9) dHex1Hex6HexNAc6 FA4G3 -
2539.9 (2539.9) dHex1Hex7HexNAc6 FA4G4 10
2742.9 (2743.0) dHex1Hex7HexNAc7 FA4G4GlcNAc -
Theoretical monoisotopic masses of the proposed glycan structures [M + Na]+ are
shown in parenthesis. HexNAc: N-acetylhexosamine; dHex: deoxyhexose; Hex:
hexose.
N-glycans have two core N-acetylglucosamine (GlcNAc); Mx, x represents the
number of mannose (Man) on core GlcNAc; F at the start represents α1,6-linked
core fucose (Fuc); A2, biantennary; A3, triantennary; A4, tetraantennary; B,
bisecting GlcNAc; Gx, x represents number of galactose (Gal) [3];G1 or [6]G1
represents that Gal is on the α1,3 or α1,6 mannose; Sx (3,6), x represents number
of sialic acids linked to Gal, the numbers in parentheses represent α2,3 or α2,6
linkage.
These mass signals have been detected from independent preparations of purified
exosomes (spectrum shown in Figure 4) and crude exosomes (data not shown).
Compatible structures considering the N-glycan biosynthetic pathway are shown.
The structures identified by NP-HPLC (Figure 3) are indicated.
doi: 10.1371/journal.pone.0078631.t002
in urinary exovesicles [32] and in tumor microvesicles [10].
Initial results from our laboratory have indicated higher
amounts of sialylated glycans by NP-HPLC in the exosomes
relatively to plasma membrane or microsomal fraction (results
not shown). Bisecting GlcNAc-containing N-glycans have been
found in exosomes (Figure 3, Figure S3 and Figure S4).
Accordingly, complex bisecting glycans have also been
described in tissues of endometrioid ovarian cancer [33], and
increased N-acetylglucosaminyltransferase III activity was
found in human serum of hepatoma patients [34] and
pancreatic carcinoma tissues [35]. However, in other types of
cancer, for example, colorectal cancer, decreases in the levels
of bisecting GlcNAc-containing structures have been observed
[36]. Furthermore, the presence of bisecting GlcNAc has been
associated with decreases in metastasis formation in several
cancers [37]. In view of this, it will be necessary to further
investigate the levels of bisecting GlcNAc in other ovarian
cancer cell lines, in human tissues of different types and stages
of ovarian cancer, and to study its specificity and functional role
in the disease.
Exosomes have been used in nanoscale cancer vaccines for
different types of cancer and although the results are
promising, further studies need to be performed to engineer
exosomes for cancer vaccine development [38]. Since
glycosylation is a major hallmark of cancer where strong
deregulation takes place one possible approach to improve the
properties of exosomes as vaccines is to remodel their
glycosylation, and in this context, knowing the detailed
glycosylation properties of exosomes is of crucial importance.
Furthermore, using LGALS3BP as a target to improve
exosomes properties as vaccines also appears an appealing
idea.
In summary, we have identified sialoglycoproteins from the
exosomes of ovarian carcinoma cells most relevant being
LGALS3BP that constitutes an exosome marker
sialoglycoprotein. Furthermore, the N-glycans from exosomes
of ovarian carcinoma cells have been characterized in detail.
The results open novel perspectives to explore the potential
roles of N-glycans in exosome biology and as markers for
ovarian cancer.
Supporting Information
Figure S1.  NP-HPLC analysis of 2-AB labeled reference
oligosaccharide standards. a, Man3GlcNAc2Fuc. b,
Man5GlcNAc2 c, Man6GlcNAc2 d, Man7GlcNAc2 e,
Man8GlcNAc2 f, Man9GlcNAc2 g, diantennary minus 2 Gal
with proximal α1,6 Fuc. h, diantennary minus 2 Gal with
bisecting GlcNAc with proximal α1,6 Fuc. i, diantennary minus
1 Gal with proximal α1,6 Fuc (C3 and C6). j, diantennary minus
1 Gal with bisecting GlcNAc with proximal α1,6 Fuc. k,
diantennary with proximal α1,6 Fuc. l, diantennary with
bisecting GlcNAc with proximal α1,6 Fuc. m, monosialylated
(2,6) diantennary minus 1 Gal with proximal α1,6 Fuc (C3 and
C6). n, monosialylated (2,6) diantennary with proximal α1,6
Fuc. o, disialylated (2,6) diantennary without proximal α1,6 Fuc.
p, diantennary minus 2 Gal minus 1 GlcNAc without proximal
α1,6 Fuc (C3). q, diantennary minus 2 Gal minus 1 GlcNAc
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with proximal α1,6 Fuc (C3). r, diantennary minus 2 Gal without
proximal α1,6 Fuc. s, diantennary minus 1 Gal minus 1 GlcNAc
without proximal α1,6 Fuc (C3). t, diantennary minus 1 Gal
minus 1 GlcNAc with proximal α1,6 Fuc (C3). diantennary
minus 1Gal without proximal α1,6 Fuc (C6). u, diantennary with
proximal α1,6 Fuc. w, triantennary (2,4) with proximal α1,6 Fuc.
v, triantennary (2,6) with proximal α1,6 Fuc. x, tetraantennary
with proximal α1,6 Fuc. y, diantennary without proximal α1,6
Fuc. z, triantennary (2,4) without proximal α1,6 Fuc. aa,
triantennary (2,6) without proximal α1,6 Fuc. ab, tetraantennary
without proximal α1,6 Fuc. ac, triantennary (2,4) minus 3 Gal
with proximal α1,6 Fuc. ad, triantennary (2,6) minus 3 Gal with
proximal α1,6 Fuc. ae, tetraantennary minus 4 Gal with
proximal α1,6 Fuc. af, triantennary (2,6) minus 3 Gal without
proximal Fuc. ag, tetraantennary minus 4 Gal without proximal
α1,6 Fuc. ah, triantennary minus 2 Gal with proximal Fuc. ai,
triantennary minus 1 Gal with proximal Fuc. aj, triantennary
minus 2 Gal without proximal α1,6 Fuc. ak, triantennary minus
1 Gal without proximal α1,6 Fuc
(PDF)
Figure S2.  MALDI/TOF-MS analysis of the total
desialylated N-glycans from crude exosomes of ovarian
carcinoma OVM cells. Only one or two possible isomeric
structures of selected peaks are presented. Graphical
representations of glycans are consistent with the
nomenclature of the Consortium for Functional Glycomics.
(PDF)
Figure S3.  LC-MS/MS structural analysis of the 2110.8 Da
2-AB labeled oligosaccharide. The fragmentation spectrum
of the triply charged ion species of a 2110.8 Da
oligosaccharide is shown that could in principle relate to one
(and more) of the structures presented in panel A) with the
structural part specific for the bisecting GlcNAc motif
highlighted. B) the annotated fragmentation spectrum. C)
excerpts of the fragmentation spectrum with fragment ions that
can only be generated by the bisecting GlcNAc motif. The first
fragment has a mass of 910.25 Da which corresponds to two
HexNAc and one Hex as well as a 2-AB label. The second
fragment has one (m/z 1038.29) or two (m/z 1056.35) water
remaining from the fragmentation of the glycosidic bonds and
in addition to the fragment shown on the left has an additional
deoxy-hexose.
(PDF)
Figure S4.  LC-MS/MS analysis of the 2313.9 Da 2-AB
labeled oligosaccharide. The fragmentation spectrum of the
triply charged ion species of a 2313.9 Da oligosaccharide at
m/z 772.0 is shown that could in principle relate to one (and
more) of the structures presented in panel A) with the structural
part specific for the bisecting GlcNAc motif highlighted. B) the
annotated fragmentation spectrum. C) An excerpt of the
fragmentation spectrum with fragment ions that can only be
generated by the bisecting GlcNAc motif. The fragment has
one (m/z 1442.28) or two (m/z 1460.39) water remaining from
the fragmentation of the glycosidic bonds.
(PDF)
Table S1.  Structures of 2-AB labeled reference
oligosaccharide standards shown in Figure S1.
(PDF)
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